GLS Pharma Limited

GLS Pharma Limited, established on September 1, 2004, is a professionally managed pharmaceutical company headquartered in New Delhi, India. The company specializes in the manufacturing and marketing of oncology and chemotherapy-related products, including chemotherapy, hematology, supportive care, and novel drug delivery systems (NDDS). GLS Pharma has a significant presence in the Indian pharmaceutical market, exporting its products to over 30 countries.

The company operates as a public limited entity with an authorized capital of ₹13 million and a paid-up capital of ₹12 million. As of April 3, 2024, GLS Pharma employed 116 professionals. In June 2022, GLS Pharma was acquired by Aurobindo Pharma, a leading Indian pharmaceutical company, enhancing its capabilities and market reach.

GLS Pharma operates a WHO GMP-certified manufacturing facility located in Jeedimetla, Hyderabad, India. This facility specializes in the production of oncology and chemotherapy-related products, ensuring adherence to stringent quality standards. The company's backward integration strategy includes the in-house manufacturing of 38 oncology active pharmaceutical ingredients (APIs), allowing GLS Pharma to control costs without compromising on quality.

GLS Pharma's leadership team comprises experienced professionals with extensive backgrounds in the pharmaceutical industry. Suresh Pathak, the founder and director, has over three decades of experience in the sector, having held leadership positions in companies such as Dabur Pharma, Zydus Cadila, MSD, Wockhardt, and Win Medicare. Other key directors include Srinivasa Ramachandra Rao Ilapakurthy, appointed on December 15, 2023, and Ravikiran Namburi, appointed on September 20, 2024.

GLS Pharma's products are registered and approved in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's focus on high-quality manufacturing and adherence to international standards has facilitated market access in these regions. Specific details regarding regulatory filings and approvals are not publicly disclosed.

GLS Pharma has expanded its presence in emerging markets across Africa, Latin America, and Southeast Asia. The company's commitment to providing affordable and high-quality oncology products has enabled it to penetrate these regions effectively. While specific information on WHO prequalification is not available, the company's adherence to international quality standards supports its market access in these areas.

GLS Pharma's geographic strategy involves a balanced approach, focusing on both domestic and international markets. The company's export activities to over 30 countries demonstrate its commitment to global expansion. By diversifying its market presence, GLS Pharma mitigates concentration risk and leverages growth opportunities across different regions.

Specific details regarding GLS Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's adherence to international quality standards suggests compliance with FDA regulations, facilitating market access in the United States.

GLS Pharma's manufacturing facility in Hyderabad is WHO GMP-certified, indicating compliance with international quality standards. While specific information regarding EU GMP certification and EDQM status is not available, the company's focus on quality manufacturing supports its potential for market access in the European Union.

GLS Pharma holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers, ensuring compliance with Indian regulatory requirements. The company's adherence to these standards facilitates its operations within India and supports its export activities.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to GLS Pharma. The company's commitment to quality manufacturing and adherence to regulatory standards suggest a strong compliance record.

GLS Pharma operates in the competitive oncology pharmaceutical sector, facing competition from both domestic and international companies. While specific market share data is not publicly available, the company's focus on high-quality, affordable oncology products positions it as a significant player in the market. The acquisition by Aurobindo Pharma in June 2022 may enhance its competitive position through increased resources and market reach.

GLS Pharma's key differentiators include its backward integration strategy, in-house manufacturing of 38 oncology APIs, and a focus on providing affordable, high-quality oncology products. The company's commitment to quality manufacturing and customer service further distinguishes it in the competitive pharmaceutical landscape.

GLS Pharma's strategic direction focuses on the oncology segment, emphasizing the development and marketing of chemotherapy and supportive care products. The company's acquisition by Aurobindo Pharma in June 2022 is expected to strengthen its position in the generics market and may provide opportunities to explore specialty pharmaceuticals and contract development and manufacturing organization (CDMO) services in the future.

GLS Pharma demonstrates a strong track record in the pharmaceutical industry, with a focus on quality manufacturing and customer service. The company's export activities to over 30 countries indicate consistent export volume and reliability. The acquisition by Aurobindo Pharma in June 2022 may further enhance its capabilities and reliability as a supplier.

Importers should verify the following certifications when considering GLS Pharma as a supplier:

• FDA Registration: Confirm the company's FDA facility registration status to ensure compliance with U.S. regulations.

• WHO GMP Certification: Verify the WHO GMP certification of the manufacturing facility to ensure adherence to international quality standards.

• EU GMP Certification: Check for EU GMP certification to facilitate market access in the European Union.

• ISO Certifications: Review any ISO certifications held by the company to assess quality management systems.

When conducting due diligence on GLS Pharma, consider the following steps:

• Regulatory Compliance: Verify the company's compliance with relevant regulatory bodies, including the FDA, WHO, and EU authorities.

• Quality Assurance: Assess the company's quality management systems and certifications to ensure product quality.

• Financial Stability: Review the company's financial statements to evaluate its financial health and stability.

• Supply Chain Reliability: Evaluate the company's supply chain processes and history to ensure consistent and reliable product delivery.

Be vigilant for any discrepancies in regulatory filings, quality certifications, or financial records, as these may indicate potential risks.